Vnitr Lek 2012, 58(Suppl 1):4-40

Doporučení pro diagnostiku a léčbu chronického srdečního selhání - ČKS 2011

J. ©pinar1,*, J. Vítovec2, J. Hradec3, I. Málek4, J. Meluzín2, L. ©pinarová2, L. Hoąková4, M. Hegarová4, O. Ludka1, M. Táborský5
1 Interní kardiologická klinika Lékařské fakulty MU a FN Brno, pracoviątě Bohunice, přednosta prof. MUDr. Jindřich ©pinar, CSc., FESC
2 I. interní kardio-angiologická klinika Lékařské fakulty MU a FN u sv. Anny v Brně, přednosta prof. MUDr. Jiří Vítovec, CSc., FESC
3 III. interní klinika 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. ©těpán Svačina, DrSc., MBA
4 Klinika kardiologie IKEM Praha, přednosta prof. MUDr. Jan Kautzner, CSc., FESC
5 I. interní klinika - kardiologická Lékařské fakulty UP a FN Olomouc, přednosta doc. MUDr. Miloą Táborský, CSc., FESC, MBA

Received: December 27, 2011; Published: February 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
©pinar J, Vítovec J, Hradec J, Málek I, Meluzín J, ©pinarová L, et al.. Doporučení pro diagnostiku a léčbu chronického srdečního selhání - ČKS 2011. Vnitr Lek. 2012;58(Supplementum 1):4-40.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Dickstein K, Cohen-Solal A, Fillippatos G et al. ESC Committee for Practice Guidelines (CPG). ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J Fail 2008; 10: 933-989. Go to original source... Go to PubMed...
    2. ©pinar J, Hradec J, Meluzín J et al. Doporučení pro diagnostiku a léčbu srdečního selhání ČKS 2006. Cor et Vasa 2007; 49: K5-K33.
    3. Hradec J. Diastolické srdeční selhání. In: Habilitační a inaugurační přednáąky na 1. lékařské fakultě UK v Praze 2004. Praha: Galen 2005: 148-154.
    4. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007; 93: 1137-1146. Go to original source... Go to PubMed...
    5. Stewart S, MacIntyre K, Hole DJ et al. More "malignant" than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail 2001; 3: 315-322. Go to original source... Go to PubMed...
    6. Rosolová H, Čech J, Simon J et al. Short to long term mortality of patients hospitalised in the Czech Republic - report from the EuroHeart Failure Survey. Eur J Heart Fail 2005; 7: 780-783. Go to original source... Go to PubMed...
    7. Cowie MR, Wood DA, Coats AJ et al. Survival of patients with a new diagnosis of heart failure: a population based study. Heart 2000; 83: 505-510. Go to original source... Go to PubMed...
    8. Bhatia RS, Tu JV, Lee DS et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006; 355: 260-269. Go to original source... Go to PubMed...
    9. Hunt SA, Abraham WT, Chin MH et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society. Circulation 2005; 112: 1825-1852. Go to original source...
    10. Leier CV. Examining the Jugular Vein Is Never in Vain. Circ Heart Fail 2010; 3: 175-177. Go to original source... Go to PubMed...
    11. Cleland JG, Swedberg K, Follath F et al. Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The Euro Heart Failure Survey Programme - a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003; 24: 442-463. Go to original source... Go to PubMed...
    12. Rame JE, Dries DL, Drazner MH. The prognostic value of the physical examination in patients with chronic heart failure. Congest Heart Fail 2003; 9: 170-178. Go to original source... Go to PubMed...
    13. Hasselblad V, Gattis Stough W, Shah MR et al. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail 2007; 9: 1064-1069. Go to original source... Go to PubMed...
    14. Maisel AS, Krishnaswamy P, Nowak RM et al. Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347: 161-167. Go to original source... Go to PubMed...
    15. Jourdain P, Jondeau G, Funck F et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 2007: 49: 1733-1739. Go to original source... Go to PubMed...
    16. ©pinar J, Vítovec J, Blaha M et al. Radiologic changes in chronic heart failure. Cor Vasa 1992; 34: 88-99.
    17. Garcia MJ, Thomas JD, Klein AL. New Doppler echocardiographic applications for the study of diastolic function. J Am Coll Cardiol 1998; 32: 865-875. Go to original source... Go to PubMed...
    18. Nagueh SF, Middleton KJ, Kopelen HA et al. Doppler tissue imaging: A noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol 1997; 30: 1527-1533. Go to original source... Go to PubMed...
    19. Ommen SR, Nishimura RA, Appleton CP et al. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: A comparative simultaneous Doppler-catheterization study. Circulation 2000; 102: 1788-1794. Go to original source... Go to PubMed...
    20. Nagueh SF, Appleton CP, Gillebert TC et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 2009; 10: 165-193. Go to original source... Go to PubMed...
    21. Paulus WJ, Tschöpe C, Sanderson JE et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007; 28: 2539-2550. Go to original source... Go to PubMed...
    22. Mehra MR, Kobashigawa J, Starling R et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates - 2006. J Heart Lung Transplant 2006; 25: 1024-1042. Go to original source... Go to PubMed...
    23. Arena R, Myers J, Abella J et al. Development of a ventilatory classification system in patients with heart failure. Circulation 2007; 115: 2410-2417. Go to original source... Go to PubMed...
    24. Cífková R, Býma S, Čeąka R et al. Prevence kardiovaskulárních onemocnění v dospělém věku. Společné doporučení českých odborných společností. Cor Vasa 2005; 47: 3-14.
    25. Lewis EF, Johnson PA, Johnson W et al. Preferences for quality of life or survival expressed by patients with heart failure. J Heart Lung Transplant 2001; 20: 1016-1024. Go to original source... Go to PubMed...
    26. Hradec J, Berka L, Táborský M. Posuzování způsobilosti kardiologických nemocných k řízení motorových vozidel. Cor et Vasa 2006; 48: K47-K51.
    27. Kloner RA, Brown M, Prisant LM et al. Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Sildenafil Study Group. Am J Hypertens 2001; 14: 70-73. Go to original source... Go to PubMed...
    28. Davis MM, Taubert K, Benin AL et al. American Heart Association; American College of Cardiology; American Association of Cardiovascular and Pulmonary Rehabilitation; American Association of Critical Care Nurses; American Association of Heart Failure Nurses; American Diabetes Association; Association of Black Cardiologists, Inc; Heart Failure Society of America; Preventive Cardiovascular Nurses Association; American Academy of Nurse Practitioners; Centers for Disease Control and Prevention and the Advisory Committee on Immunization. Influenza vaccination as secondary prevention for cardiovascular disease: a science advisory from the American Heart Association/American College of Cardiology. J Am Coll Cardiol 2006; 48: 2610. Go to original source...
    29. Pilote L, Abrahamowitz M, Rodrigues E et al. Mortality rates in elderly patients who take different angiotenzin enzyme converting inhibitors after acute myocardial infarction: a class effect? Ann Intern Med 2004; 141: 102-112. Go to original source... Go to PubMed...
    30. Hansen ML, Gislason GH, Køber L et al. Different angiotenzin converting enzyme inhibitors have similar clinical efficacy after myocardial infarction. Br J Clin Pharmacol 2008; 65: 217-223. Go to original source... Go to PubMed...
    31. Packer M, Poole-Wilson PA, Armstrong PW et al. Comparative effects of low and high doses of the angiotenzin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation 1999; 100: 2312-2318. Go to original source... Go to PubMed...
    32. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-1435. Go to original source... Go to PubMed...
    33. EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-788.
    34. Yusuf S, Sleight P, Pogue J et al. Effects of an angiotenzin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153. Go to original source...
    35. McMurray J, Cohen-Solal A, Dietz R et al. Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotenzin receptor blockers in heart failure: putting guidelines into practice. Eur J Heart Fail 2005; 7: 710-721. Go to original source... Go to PubMed...
    36. Cleland J, Tendera M, Adamus J et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006; 27: 2338-2345. Go to original source... Go to PubMed...
    37. Massie BM, Carson PE, McMurray JJ et al. I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008; 359: 2456-2467. Go to original source... Go to PubMed...
    38. Yusuf S, Pfeffer MA, Swedberg K et al. CHARM Investigators and Committees. Effects of candesartan in patients with CHF and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777-781. Go to original source... Go to PubMed...
    39. Konstam MA, Neaton JD, Drexler H et al. HEAAL Investigators. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009: 374: 1840-1848. Go to original source... Go to PubMed...
    40. Dargie HJ. The Capricorn Investigators: Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001; 357: 1385-1390. Go to original source... Go to PubMed...
    41. Vitovec J, ©pinar J. Beta-blokátory v léčbě chronického srdečního selhání. Vnitř Lék 2000; 46: 161-165. Go to PubMed...
    42. Remme WJ. Should ACE inhibitors Always be First-Line Therapy in Heart Failure? Lessons from the CARMEN Study. Cardiovasc Drugs Ther 2003; 17: 107-109. Go to original source... Go to PubMed...
    43. Willenheimer R, van Veldhuisen DJ, Silke B et al. CIBIS III Investigators. Effect on Survival and Hospitalization of Initiating Treatment for Chronic Heart Failure With Bisoprolol Followed by Enalapril, as Compared With the Opposite Sequence Results of the Randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 2005; 112: 2426-2435. Go to original source... Go to PubMed...
    44. Anand IS, Florea VG. Diuretics in chronic heart failure - benefits and hazards. Europ Heart J 2001; 3 (Suppl G): G8-G18. Go to original source...
    45. Haller C. Diuretics in congestive heart failure: new evidence for old problems. Nephrol Dial Transplant 1999; 14: 1358-1360. Go to original source... Go to PubMed...
    46. Reyes AJ, Taylor SH. Diuretics in Cardiovascular Therapy: The new Clinicopharmacological Bases That Matter. Cardiovasc Drug Ther 1999; 13: 371-398. Go to original source... Go to PubMed...
    47. Konstam MA, Gheorghiade M, Burnett JC Jr et al. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007; 297: 1319-1331. Go to original source... Go to PubMed...
    48. Zannad F, McMurray JJ, V Krum H et al. EMPHASIS-HF Study Group. Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. N Engl J Med 2011; 364: 11-21. Go to original source... Go to PubMed...
    49. Berry C, McMurray JJ. Serious adverse events experienced by patients with chronic heart failure taking spironolactone. Heart 2001; 85: E8. Go to original source... Go to PubMed...
    50. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525-533. Go to original source... Go to PubMed...
    51. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002; 347: 1403-1411. Go to original source... Go to PubMed...
    52. Hood WB Jr, Dans AL, Guyatt GH et al. Digitalis for treatment of congestive heart failure in patients in sinus rhythm: a systematic review and meta-analysis. J Card Fail 2004; 10: 155-164. Go to original source... Go to PubMed...
    53. Rathore SS, Curtis JP, Wang Y et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003; 289: 871-878. Go to original source... Go to PubMed...
    54. Beemath A, Stein PD, Skaf E et al. Risk of venous thromboembolism in patients hospitalized with heart failure. Am J Cardiol 2006; 98: 793-795. Go to original source... Go to PubMed...
    55. Witt BJ, Gami AS, Ballman KV et al. The incidence of ischemic stroke in chronic heart failure: a meta-analysis. J Card Fail 2007; 13: 489-496. Go to original source... Go to PubMed...
    56. de Peuter OR, Kok WE, Torp-Pedersen C et al. Systolic heart failure: a prothrombotic state. Semin Thromb Hemost 2009; 35: 497-504. Go to original source... Go to PubMed...
    57. Gibbs CR, Blann AD, Watson RD et al. Abnormalities of Hemorheological, Endothelial, and Platelet Function in Patients With Chronic Heart Failure in Sinus Rhythm: effects of angiotenzin-converting enzyme inhibitor and beta-blocker therapy. Circulation 2001; 103: 1746-1751. Go to original source... Go to PubMed...
    58. Bettari L, Fiuzat M, Becker R et al. Thromboembolism and Antithrombotic Therapy in Patients With Heart Failure in Sinus Rhythm Current Status and Future Directions. Circ Heart Fail 2011; 4: 361-368. Go to original source... Go to PubMed...
    59. Cokkinos DV, Harabalopoulos GC, Kostis JB et al. HELLAS Investigators. Efficacy of antithrombotic therapy in chronic heart failure. Eur J Heart Fail 2006; 8: 428-432. Go to original source... Go to PubMed...
    60. Camm AJ, Kirchhof P, Lip GY et al. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429. Go to original source... Go to PubMed...
    61. Kjekshus J, Apetrei E, Barrios V et al. CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 2248-2261. Go to original source... Go to PubMed...
    62. GISSI-HF Investigators. Tavazzi L, Maggioni AP, Marchioli R et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 1231-1239. Go to original source... Go to PubMed...
    63. McMurray JJ, Kjekshus J, Gullestad L et al. CORONA Study Group. Effects of statin therapy according to plasma high sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure trial (CORONA): a retrospective analysis. Circulation 2009; 120: 2188-2196. Go to original source... Go to PubMed...
    64. Cleland JG, McMurray JJ, Kjekshus J et al. CORONA Study Group. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: Prediction of cardiovascular events and interaction with the effects of rosuvastatin: A report from CORONA (Controlled Rosuvastatin Multinational trial in Heart Failure). J Am Coll Cardiol 2009; 54: 1850-1859. Go to original source... Go to PubMed...
    65. Hradec J. Má význam podávání statinů u nemocných se srdečním selháním? Interní Med 2008; 10: 216-218.
    66. Fox K, Ford I, Steg PG et al. BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 807-816. Go to original source... Go to PubMed...
    67. Swedberg K, Komajda M, Böhm M et al. SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376: 886-894. Go to original source... Go to PubMed...
    68. Hradec J, Krupička J, Janota T. Budeme léčit srdeční selhání podle plazmatické koncentrace natriuretických peptidů? Čas Lék čes 2009; 148: 383-388.
    69. Dormans TP, Huige RM, Gerlag PG. Chronic intermittent hemofiltration and hemodialysis in end stage chronic heart failure with oedema refractory to high dose frusemide. Heart 1996; 75: 349-351. Go to original source... Go to PubMed...
    70. Giglioli C, Landi D, Cecchi E et al. Effects of ULTRAfiltration vs DiureticS on clinical, biohumoral and haemodynamic variables in patients with deCOmpensated heart failure: the ULTRADISCO study. Eur J Heart Fail 2011; 13: 337-346. Go to original source... Go to PubMed...
    71. Jaski BE, Ha J, Denys BG et al. Peripherally inserted veno-venous ultrafiltration for rapid treatment of volume overloaded patients. J Card Fail 2003; 9: 227-231. Go to original source... Go to PubMed...
    72. Lachmanová J. Očiątovací metody krve. Praha: Grada 1999.
    73. Táborský M, Kautzner J, Byteąník J et al. Zásady pro implantace kardiostimulátorů, implantabilních kardioverterů-defibrilátorů a systémů pro srdeční resynchronizační léčbu 2009. Cor Vasa 2009; 51: 602-614. Go to original source...
    74. Dickstein K, Vardas PE, Auricchio A et al. 2010 Focussed update of ESC guidelines on device therapy in heart failure. Eur Heart J 2010; do:10.1093/eurhearj/ehq337.
    75. Al Majed NS, McAlister FA, Bakal JA et al. Meta-analysis: Cardiac resynchronization therapy for patients with less symptomatic heart failure. Ann Intern Med 2011; 154: 401-412. Go to original source... Go to PubMed...
    76. Auricchio A, Prinzen FW. Non-responders to cardiac resynchronization therapy - the magnitude of the problem and the issues. Circ J 2011; 75: 521-527. Go to original source... Go to PubMed...
    77. Dickstein K, Bogale N, Priori S et al. National Coordinators. The European cardiac resynchronization therapy survey. Eur Heart J 2009; 30: 2450-2460. Go to original source... Go to PubMed...
    78. Auricchio A, Stellbrink C, Sack S et al. Pacing Therapies in Congestive Heart Failure (PATH-CHF) Study Group. Long-term clinical effect of hemodynamically optimized cardiac resynchronization therapy in patients with heart failure and ventricular conduction delay. J Am Coll Cardiol 2002; 39: 2026-2033. Go to original source... Go to PubMed...
    79. Bristow MR, Saxon LA, Boehmer J et al. Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrilator in advanced chronic heart failure. N Engl J Med 2004; 350: 2140-2150. Go to original source... Go to PubMed...
    80. Feldman AM, de Lissovoy G, Bristow MR et al. Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. J Am Coll Cardiol 2005; 46: 2311-2321. Go to original source... Go to PubMed...
    81. Cleland JG, Daubert JC, Erdmann E et al. Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and heart failure. N Engl J Med 2005; 352: 1539-1549. Go to original source... Go to PubMed...
    82. Rivero-Ayerza M, Theuns DA, Garcia-Garcia HM et al. Effects of cardiac resynchronization therapy on overall mortality and mode of death: a meta-analysis of randomized controlled trials. Eur Heart J 2006; 27: 2682-2688. Go to original source... Go to PubMed...
    83. Chung ES, Leon AR, Tavazzi L et al. Results of the Predictors of Response to CRT (PROSPECT) trial. Circulation 2008; 117: 2608-2616. Go to original source... Go to PubMed...
    84. Abraham WT, Fisher WG, Smith AL et al. MIRACLE Study Group; Multicenter Insync Randomized Clinical Evaluation. Cardiac resynchronization in chronic heart failure. N Engl Med 2002; 346: 1845-1853. Go to original source... Go to PubMed...
    85. Moss AJ, Hall WJ, Cannon DS et al. MADIT-CRT Trial Investigators. Cardiac-resynchronization therapy for the prevention of heart-failure events (MADIT-CRT). N Engl J Med 2009; 361: 1329-1338. Go to original source... Go to PubMed...
    86. Linde C, Gold M, Abraham WT et al. REVERSE Study Group. Rationale and design of a randomized controlled trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with asymptomatic left ventricular dysfunction with previous symptoms or mild heart failure - the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. Am Heart J 2006; 151: 288-294. Go to original source... Go to PubMed...
    87. Daubert C, Gold MR, Abraham WT et al. REVERSE Study Group. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial. J Am Coll Cardiol 2009; 54: 1837-1846. Go to original source... Go to PubMed...
    88. Gasparini M, Auricchio A, Metra M et al. Multicentre Longitudinal Observational Study (MILOS) Group. Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of performing atrioventricular junction ablation in patients with permanent atrial fibrillation. Eur Heart J 2008; 29: 1644-1652. Go to original source... Go to PubMed...
    89. Gasparini M, Steinberg JS, Arshad A et al. Resumption of sinus rhythm in patients with heart failure and permanent atrial fibrillation undergoing cardiac resynchronization therapy: a longitudinal observational study. Eur Heart J 2010; 31: 976-983. Go to original source... Go to PubMed...
    90. Kindermann M, Hennen B, Jung J et al. Biventricular versus conventional right ventricular stimulation for patients with standard pacing indication and left ventricular dysfunction: the Homburg Biventricular Pacing Evaluation (HOBIPACE). J Am Coll Cardiol 2006; 47: 1927-1937. Go to original source... Go to PubMed...
    91. Yu CM, Chan JY, Zhang Q et al. Biventricular pacing in patients with bradycardia and normal ejection fraction. N Engl J Med 2009; 361: 2123-2134. Go to original source... Go to PubMed...
    92. Deng MC, Edwards LB, Hertz MI. et al. International Society for Heart and Lung Transplantation. Mechanical circulatory support device database of the International Society for Heart and Lung Transplantation: third annual report - 2005. J Heart Lung Transplant 2005; 24: 1182-1187. Go to original source... Go to PubMed...
    93. Kettner J. Mechanické podpory krevního oběhu. Cor Vasa 2003; 45: 437-443.
    94. Pirk J, Málek I et al. Transplantace srdce. 1. vyd. Praha: Karolinum 2008.
    95. Kirklin JK, Naftel DC, Kormos RL et al. Second INTERMACS annual report: More than 1,000 primary left ventricular assist device implants. J Heart Lung Transplant 2010; 29: 1-10. Go to original source... Go to PubMed...
    96. Zimpfer D, Zrunek P, Sandner S et al. Posttransplant survival after lowering fixed pulmonary hypertension using left ventricular devices. Eur J Cardiothorac Surg 2007; 31: 698-702. Go to original source... Go to PubMed...
    97. Florian M, Málek I, Pirk J et al. Výsledky chirurgické revaskularizace myokardu u pacientů s významnou předoperační systolickou dysfunkcí levé komory. Cor Vasa 2001; 43: 85-88.
    98. Velazquez EJ, Kerry LL, Deja MA et al. STICH Investigators. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med 2011; 364: 1607-1616. Go to original source... Go to PubMed...
    99. Jones RH, Velazques EJ, Michler RE et al. Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med 2009; 360: 1-13. Go to original source... Go to PubMed...
    100. Mehra MR, Kobashigawa J, Starlig R et al. Listing criteria for Heart Transplantation: International Society for Heart and Lung Transplantation Guidelines for the Care of Cardiac transplant candidates - 2006. J Heart Lung Transpl 2006; 25: 1024-1042. Go to original source... Go to PubMed...
    101. Goodlin SJ, Hauptman PJ, Arnold R et al. Consensus Statement: Palliative and Supportive Care in Advanced Heart Failure. J Card Fail 2004; 10: 200-209. Go to original source... Go to PubMed...
    102. Hershberger RE, Nauman D, Walker TL et al. Care Processes and Clinical Outcomes of Continuous Outpatient Support with Inotropes (COSI) in Patients with Refractory Endstage Heart Failure. J Card Fail 2003; 9: 180-187. Go to original source... Go to PubMed...
    103. Stevenson LW. The Cul-de-Sac at the End of the Road. J Cardiac Failure 2003; 9: 188-191. Go to original source... Go to PubMed...
    104. Jaarsma T, Beattie JM, Ryder M et al. Advanced Heart Failure Study Group of the HFA of the ESC. Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2009: 11: 433-443. Go to original source... Go to PubMed...
    105. Baker DW. Prevention of heart failure. J Card Fail 2002; 8: 333-346. Go to original source... Go to PubMed...
    106. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001; 358: 1305-1315. Go to original source... Go to PubMed...
    107. ©pinar J, Vítovec J. Kontrola krevního tlaku u diabetiků s ischemickou chorobou srdeční. Kardiol Rev 2010; 12: 128-130.
    108. Mancia G, Laurent S, Agabiti-Rosei L et al. European Society of Hypertension. Reappraisal of European guidelines on hypertension management: a European Society of hypertension Task Force document. J Hypertens 2009; 27: 2121-2158. Go to original source... Go to PubMed...
    109. MacDonald MR, Petrie MC, Hawkins NM et al. Diabetes, left ventricular systolic dysfunction, and chronic heart failure. Eur Heart J 2008; 29: 1224-1240. Go to original source... Go to PubMed...
    110. Rydén L, Standl E, Bartnik M et al. Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88-136.
    111. McAlister FA, Ezekowitz J, Tonelli M et al. Renal insufficiency and heart failure: prognostic and terapeutic implications from prospective cohort study. Circulation 2004; 109: 1004-1009. Go to original source... Go to PubMed...
    112. Smith GL, Lichtman JH, Bracken MB et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol 2006; 47: 1987-1996. Go to original source... Go to PubMed...
    113. Shlipak MG, Massie BM. The clinical challenge of cardorenal syndrom. Circulation 2004; 110: 1514-1517. Go to original source... Go to PubMed...
    114. Shlipak MG. Pharmacotherapy for Heart Failure in Patients with Renal Insuficiency. Ann Int Med 2003; 138: 917-924. Go to original source... Go to PubMed...
    115. Hillege HL, Nitsch D, Pfeffer MA. Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Investigators. Renal function as a Predictor of Outcome in a Broad Spectrum of Patients with Heart Failure. Circulation 2006; 113: 671-678. Go to original source... Go to PubMed...
    116. Málek F, Havrda M, Frühaufová Z et al. Multidisciplinární přístup v péči o nemocné s kardiorenálním syndromem - první zkuąenosti. Cor Vasa 2006; 48: K185.
    117. Spinar J, Ludka O, Dusek L et al. Neurohumoral Activity, Heart Failure and Prognosis in Patients with End-Stage Renal Disease Treated by Hemodialysis. Kidney Blood Press Res 2007; 30: 347-357. Go to original source... Go to PubMed...
    118. Rutten FH, Cramer MJ, Lammers JW et al. Heart failure and chronic obstructive pulmonary disease: an ignored combination? Eur J Heart Fail 2006; 8: 706-711. Go to original source... Go to PubMed...
    119. Macchia A, Monte S, Romero M et al. The prognostic influence of chronic obstructive pulmonary disease in patients hospitalised for chronic heart failure. Eur J Heart Fail 2007; 9: 942-948. Go to original source... Go to PubMed...
    120. Rutten FH, Cramer MJ, Grobbee DE et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J 2005; 26: 1887-1894. Go to original source... Go to PubMed...
    121. Hawkins NM, Petrie MC, MacDonald MR et al. Heart Failure and Chronic Obstructive Pulmonary Disease The Quandary of Beta-Blockers and Beta-Agonists. J Am Coll Cardiol 2011; 57: 2127-2138. Go to original source... Go to PubMed...
    122. The Stroke Prevention in Atrial Fibrilation Investigators. Predictors in thromboembolism in atrial fibrillation. I. Clinical features of patients at risk. Ann Intern Medicine 1992; 116: 1-5. Go to original source... Go to PubMed...
    123. Conolly SJ, Ezekowitz MD, Yusuf S et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151. Go to original source... Go to PubMed...
    124. Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6 500 patients in randomised trials. Lancet 1997; 350: 1417-1424.
    125. Byteąník J. Doporučené postupy pro diagnostiku a léčbu komorových arytmií. Cor Vasa 2005; 47: 41-58.
    126. Grimm W, Christ M, Bach J et al. Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy: results of the Marburg Cardiomyopathy Study. Circulation 2003; 108: 2883-2891. Go to original source... Go to PubMed...
    127. Lupínek P. Význam s léčba anémie u chronického srdečního selhání. Cor Vasa 2004; 46: 281-284.
    128. Silveberg DS, Wexler D, Sheps D et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneuous erythropoetin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001; 37:1775-1780. Go to original source... Go to PubMed...
    129. McMurray JJ, Anand IS, Diaz R et al. RED-HF Committees and Investigators. Design of reduction of events with darbopoetin alfa in heart failure (RD-HF): a phase III, anaemia correction, morbidity-mortality trial. Eur J Heart Fail 2009; 11: 795-801. Go to original source... Go to PubMed...
    130. Pöss J, Jacobshagen C, Ukena C et al. Hotlines and clinical updates presented at he German Cardiac Society Meeting 2010: FAIR-HF, CIPAMI, LIPSIA, Handheld-BNP, PEPCAD III, remote ischaemic conditioning, CERTIFY, PreSCD-II, German Myocardial Infarction Registry, DiaRegis. Clin Res Cardiol 2010; 99: 411-417. Go to original source... Go to PubMed...
    131. Cleland JG. Anticoagulant and antiplatelet therapy in heart failure. Curr Opin Cardiol 1997; 12: 276-287. Go to original source... Go to PubMed...
    132. Dries DL, Rosenberg YD, Waclawiw A et al. Ejection fraction and risk of tromboembolitic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials. J Am Coll Cardiol 1997; 29: 1074-1080. Go to original source... Go to PubMed...
    133. Hradec J. Srdce a endokrinní onemocnění. In: Aschermann M, Widimský P, Veselka J (eds). Kardiologie. 2. díl. Praha: Galén 2004: 1369-1382.
    134. Rutlege T, Reis VA, Linke SE et al. Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol 2006; 48: 1527-1537. Go to original source...
    135. Sherwood A, Blumenthal JA, Trivedi R et al. Relationship of depression to death or hospitalization in patients with heart failure. Arch Intern Med 2007; 167: 367-373. Go to original source... Go to PubMed...
    136. Swenson JR, O'Connor CM, Barton D et al. Sertraline Antidepressant Heart Attack Randomized Trial (SADHART) Group. Influence of depression and effect to treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. Am J Cardiol 2003; 92: 1271-1276. Go to original source... Go to PubMed...
    137. Lanfranchi PA, Somers VK, Braghiroli A et al. Central sleep apnea in left ventricular dysfunction: prevalence and implications for arrhytmic risk. Circulation 2003; 107: 727-732. Go to original source... Go to PubMed...
    138. Shahar E, Whitney CW, Redline S et al. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. Am J Respir Crit Care Med 2001; 163: 19-25. Go to original source... Go to PubMed...
    139. The Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). ESC Guidelines on the management of cardiovascular diseases during pregnancy. Eur Heart J 2011; 32: doi:10.1093/eurheartj/ehr218. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.